



March 10, 2016
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

**Onconova Announces Publication of Results from the ONTIME Trial
for rigosertib in MDS**

TOKYO, Japan, March 10, 2016 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") announced publication of clinical study results for rigosertib on March 9, 2016 (EST). Symbio obtained the licensing rights for rigosertib in July 2011 and retains the development rights for Japan and Korea.

This announcement follows publication of the ONTIME trial results of intravenous (IV) rigosertib in higher-risk myelodysplastic syndromes (HR-MDS) in *The Lancet Oncology* (online).

The new Phase 3 study with IV rigosertib in HR-MDS patients following failure of hypomethylating agents (HMA) treatment was initiated in 4Q 2015, for which study Symbio will also shortly begin enrolling patients in Japan.

For more details in this press release, please visit Onconova's homepage at

<http://investor.onconova.com/releases.cfm>

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About Myelodysplastic Syndromes (MDS)

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in the number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as two blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower-risk MDS and HR-MDS.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.